Literature DB >> 18847401

Current challenges in treating MRSA: what are the options?

Natasha V D V Ratnaraja1, Peter M Hawkey.   

Abstract

This review looks at the challenges facing the worldwide community with the increasing problem of methicillin resistance in Staphylococcus aureus. The epidemiology and natural history of community-associated methicillin-resistant Staphylococcus aureus and the challenge of control is discussed. Options for treatment and review of key antimicrobial agents acting against methicillin-resistant S. aureus, both currently in use and in development, are addressed. There are a number of new agents, the place of which in therapeutic regimens is yet to emerge. The review attempts to inform the reader of the probable position of these agents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18847401     DOI： 10.1586/14787210.6.5.601

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  6 in total

1.  Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Authors:  Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

2.  In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Authors:  Michael J Pucci; Steven D Podos; Jane A Thanassi; Melissa J Leggio; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

3.  Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus.

Authors:  Kyungae Lee; Jennifer Campbell; Jonathan G Swoboda; Gregory D Cuny; Suzanne Walker
Journal:  Bioorg Med Chem Lett       Date:  2010-01-20       Impact factor: 2.823

4.  In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Authors:  Céline Vidaillac; Steve N Leonard; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

5.  Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.

Authors:  Kenneth S Thomson; Richard V Goering
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

Review 6.  Recurrent Challenges for Clinicians: Emergence of Methicillin-Resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options.

Authors:  Bansidhar Tarai; Poonam Das; Dilip Kumar
Journal:  J Lab Physicians       Date:  2013-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.